Marta Sitges1,2, Blanca Boluda3, Ana Garrido4, Mireia Morgades1, Isabel Granada1, Eva Barragan3, Montserrat Arnan5, Josefina Serrano6, Mar Tormo7, Juan Miguel Bergua8, Mercedes Colorado9, Olga Salamero10, Jordi Esteve11, Celina Benavente12, Manuel Pérez-Encinas13, Rosa Coll2, Josep-Maria Martí-Tutusaus14, Salut Brunet4, Jorge Sierra4, Miguel Ángel Sanz3, Pau Montesinos3, Josep-Maria Ribera1, Susana Vives1. 1. Hematology Departments of ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain. 2. ICO-Hospital Universitari Doctor Josep Trueta, Girona, Spain. 3. Hospital Universitari i Politècnic La Fe, Valencia, Spain. 4. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 5. ICO-Hospital Duran i Reynals, IDIBELL, L'Hospitalet de Llobregat, Llobregat, Spain. 6. Hospital Universitario Reina Sofía, Córdoba, Spain. 7. Hospital Clínico Universitario, Valencia, Spain. 8. Hospital San Pedro de Alcántara, Cáceres, Spain. 9. Hospital Universitario Marqués de Valdecilla, Santander, Spain. 10. Hospital Universitari Vall d'Hebron/VHIO, Barcelona, Spain. 11. Hospital Clínic, Barcelona, Spain. 12. Hospital Clínico San Carlos, Madrid, Spain. 13. Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain. 14. Hospital Universitari Mútua de Terrassa, Terrassa, Spain.
Abstract
INTRODUCTION: Inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) is a rare poor prognosis cytogenetic abnormality present in acute myeloid leukemia (AML) and other myeloid neoplasms. OBJECTIVE: The aim of this study was to evaluate the outcome of a cohort of 61 patients with newly diagnosed AML with inv(3)/t(3;3) treated with homogeneous intensive chemotherapy protocols conducted by the Spanish PETHEMA and CETLAM cooperative groups between 1999 and 2017. METHODS: In this retrospective study the main clinical and biologic parameters were collected. The complete response (CR) rate, the cumulative incidence of relapse (CIR) and the overall survival (OS) were calculated. An analysis of prognostic factors for survival was performed. RESULTS: Sixty-one patients received induction and only 18 (29%) achieved CR (median age, 46 years). Allogeneic hematopoietic stem cell transplantation (alloHSCT) was performed in 36 patients (59%), 15 with active disease. One- and 4-year CIR were 52% and 56%. One- and 4-year OS probabilities were 41% and 13%. By multivariate analysis monosomal karyotype (MK) was associated with poorer OS (HR 2.0, P = .017). CONCLUSION: Inv(3)/t(3;3) AML is a poor prognosis entity with low response to standard chemotherapy and to alloHSCT because of frequent and early relapse. MK was associated with a poorer prognosis. Improved therapeutic strategies are clearly needed.
INTRODUCTION: Inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) is a rare poor prognosis cytogenetic abnormality present in acute myeloid leukemia (AML) and other myeloid neoplasms. OBJECTIVE: The aim of this study was to evaluate the outcome of a cohort of 61 patients with newly diagnosed AML with inv(3)/t(3;3) treated with homogeneous intensive chemotherapy protocols conducted by the Spanish PETHEMA and CETLAM cooperative groups between 1999 and 2017. METHODS: In this retrospective study the main clinical and biologic parameters were collected. The complete response (CR) rate, the cumulative incidence of relapse (CIR) and the overall survival (OS) were calculated. An analysis of prognostic factors for survival was performed. RESULTS: Sixty-one patients received induction and only 18 (29%) achieved CR (median age, 46 years). Allogeneic hematopoietic stem cell transplantation (alloHSCT) was performed in 36 patients (59%), 15 with active disease. One- and 4-year CIR were 52% and 56%. One- and 4-year OS probabilities were 41% and 13%. By multivariate analysis monosomal karyotype (MK) was associated with poorer OS (HR 2.0, P = .017). CONCLUSION: Inv(3)/t(3;3) AML is a poor prognosis entity with low response to standard chemotherapy and to alloHSCT because of frequent and early relapse. MK was associated with a poorer prognosis. Improved therapeutic strategies are clearly needed.
Authors: Christine Birdwell; Warren Fiskus; Tapan M Kadia; Courtney D DiNardo; Christopher P Mill; Kapil N Bhalla Journal: Blood Cancer J Date: 2021-03-22 Impact factor: 11.037
Authors: Alex Bataller; Ana Garrido; Francesca Guijarro; Guadalupe Oñate; Marina Diaz-Beyá; Montserrat Arnan; Mar Tormo; Susana Vives; María Paz Queipo de Llano; Rosa Coll; David Gallardo; Ferran Vall-Llovera; Lourdes Escoda; Antonio Garcia-Guiñon; Olga Salamero; Antònia Sampol; Brayan M Merchan; Joan Bargay; Sandra Castaño-Díez; Daniel Esteban; Aina Oliver-Caldés; Andrea Rivero; Pablo Mozas; Mònica López-Guerra; Marta Pratcorona; Lurdes Zamora; Dolors Costa; Maria Rozman; Josep F Nomdedéu; Dolors Colomer; Salut Brunet; Jorge Sierra; Jordi Esteve Journal: Blood Adv Date: 2022-02-22
Authors: Nigel H Russell; Sean M Devlin; Brian J P Huntly; Elli Papaemmanuil; Yanis Tazi; Juan E Arango-Ossa; Yangyu Zhou; Elsa Bernard; Ian Thomas; Amanda Gilkes; Sylvie Freeman; Yoann Pradat; Sean J Johnson; Robert Hills; Richard Dillon; Max F Levine; Daniel Leongamornlert; Adam Butler; Arnold Ganser; Lars Bullinger; Konstanze Döhner; Oliver Ottmann; Richard Adams; Hartmut Döhner; Peter J Campbell; Alan K Burnett; Michael Dennis Journal: Nat Commun Date: 2022-08-08 Impact factor: 17.694